Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation
ClinicalTrials.gov · NCT07382024 · Registry updated: 2026-06-12
- Condition / research focus
- Atrial Fibrillation Ablation; Persistent Atrial Fibrillation; Obesity & Overweight
- Sponsor
- National Taiwan University Hospital
- Countries with listed sites
- Taiwan
- Registry dates and results
- Start: 2026-06-16. Completion: 2028-07-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Tirzepatide (drug)
- Standard Care (in control arm) (other)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- National Taiwan University Hospital Cardiovascular CenterTaipei, Taiwan